{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T23:43:47Z","timestamp":1787874227363,"version":"build-2784847793"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002468","name":"Dong-A University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002468","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.esmoop.2025.106018","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T01:20:53Z","timestamp":1769044853000},"page":"106018","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Phase II trial, multicenter, first-line paclitaxel-avelumab treatment of inoperable angiosarcoma (KCSG UN 18-15)"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8321-4113","authenticated-orcid":false,"given":"H.R.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9766-1531","authenticated-orcid":false,"given":"J.E.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5037-0523","authenticated-orcid":false,"given":"Y.J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.K.","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-W.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-Y.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5396-6533","authenticated-orcid":false,"given":"S.-A.","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.Y.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.esmoop.2025.106018_bib1","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(10)70023-1","article-title":"Angiosarcoma","volume":"11","author":"Young","year":"2010","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.106018_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002990","article-title":"Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)","volume":"9","author":"Wagner","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1016\/j.esmoop.2025.106018_bib3","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/00000478-200210000-00009","article-title":"Angiosarcoma arising in hemangioma\/vascular malformation: report of four cases and review of the literature","volume":"26","author":"Rossi","year":"2002","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"10.1016\/j.esmoop.2025.106018_bib4","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/1097-0142(20010515)91:10<1914::AID-CNCR1214>3.0.CO;2-3","article-title":"Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group","volume":"91","author":"Coindre","year":"2001","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.esmoop.2025.106018_bib5","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1093\/annonc\/mdm381","article-title":"Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases","volume":"18","author":"Fayette","year":"2007","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.106018_bib6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/00130404-200505000-00011","article-title":"A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy","volume":"11","author":"Fury","year":"2005","journal-title":"Cancer J"},{"issue":"5","key":"10.1016\/j.esmoop.2025.106018_bib7","doi-asserted-by":"crossref","first-page":"247","DOI":"10.12788\/cutis.0767","article-title":"Treatment of angiosarcoma of the head and neck: a systematic review","volume":"111","author":"Houpe","year":"2023","journal-title":"Cutis"},{"key":"10.1016\/j.esmoop.2025.106018_bib8","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1634\/theoncologist.7-4-348","article-title":"The use of chemotherapy in soft-tissue sarcomas","volume":"7","author":"Spira","year":"2002","journal-title":"Oncologist"},{"issue":"32","key":"10.1016\/j.esmoop.2025.106018_bib9","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1200\/JCO.2008.17.3146","article-title":"Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study","volume":"26","author":"Penel","year":"2008","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.esmoop.2025.106018_bib10","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1200\/JCO.2015.60.8505","article-title":"Paclitaxel given once per week with or without bevacizumab in patients with advanced angiosarcoma: a randomized phase II yrial","volume":"33","author":"Ray-Coquard","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.106018_bib11","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1001\/jamaoncol.2021.3547","article-title":"Efficacy and safety of TRC105 plus pazopanib vs pazopanib alone for treatment of patients with advanced angiosarcoma: a randomized clinical trial","volume":"8","author":"Jones","year":"2022","journal-title":"JAMA Oncol"},{"issue":"19","key":"10.1016\/j.esmoop.2025.106018_bib12","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1200\/JCO.2008.20.4495","article-title":"Phase II study of sorafenib in patients with metastatic or recurrent sarcomas","volume":"27","author":"Maki","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.106018_bib13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13073-020-00753-2","article-title":"Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from genomic sequencing","volume":"12","author":"Boichard","year":"2020","journal-title":"Genome Med"},{"issue":"3","key":"10.1016\/j.esmoop.2025.106018_bib14","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","article-title":"Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials","volume":"19","author":"D'Angelo","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.106018_bib15","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/cncr.23571","article-title":"Cutaneous soft tissue sarcoma incidence patterns in the U.S. : an analysis of 12,114 cases","volume":"113","author":"Rouhani","year":"2008","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.esmoop.2025.106018_bib16","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1002\/(SICI)1097-0142(19960601)77:11<2400::AID-CNCR32>3.0.CO;2-Z","article-title":"Angiosarcoma. A report of 67 patients and a review of the literature","volume":"77","author":"Mark","year":"1996","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2025.106018_bib17","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1245\/s10434-006-9335-y","article-title":"Treatment and outcome of 82 patients with angiosarcoma","volume":"14","author":"Abraham","year":"2007","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.106018_bib18","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1245\/s10434-009-0569-3","article-title":"Outcome of locally recurrent and metastatic angiosarcoma","volume":"16","author":"Lahat","year":"2009","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.106018_bib19","doi-asserted-by":"crossref","first-page":"203","DOI":"10.7181\/acfs.2023.00409","article-title":"Current understanding of angiosarcoma: disease biology and evolving treatment","volume":"24","author":"Kim","year":"2023","journal-title":"Arch Craniofac Surg"},{"issue":"1","key":"10.1016\/j.esmoop.2025.106018_bib20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctrv.2005.10.003","article-title":"Adult soft tissue sarcomas: conventional therapies and molecularly targeted approaches","volume":"32","author":"Mocellin","year":"2006","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.esmoop.2025.106018_bib21","first-page":"1941","article-title":"Soft tissue sarcomas of adults: state of the translational science","volume":"9","author":"Borden","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2025.106018_bib22","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s002800050027","article-title":"Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study","volume":"45","author":"Merimsky","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.106018_bib23","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/annonc\/mdr066","article-title":"Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network","volume":"23","author":"Stacchiotti","year":"2012","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.106018_bib24","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/cam4.5147","article-title":"Single-agent gemcitabine in patients with advanced, pre-treated angiosarcoma: a multicenter, retrospective study","volume":"12","author":"Watson","year":"2023","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.esmoop.2025.106018_bib25","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/cncr.22822","article-title":"Docetaxel: a therapeutic option in the treatment of cutaneous angiosarcoma: report of 9 patients","volume":"110","author":"Nagano","year":"2007","journal-title":"Cancer"},{"issue":"19","key":"10.1016\/j.esmoop.2025.106018_bib26","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1200\/JCO.2008.20.9890","article-title":"Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas","volume":"27","author":"George","year":"2009","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.esmoop.2025.106018_bib27","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.10532","article-title":"Phase II intergroup study of sorafenib (S) in advanced soft tissue sarcomas (STS): SWOG 0505","volume":"26","author":"Ryan","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.106018_bib28","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s12254-017-0365-x","article-title":"Anti-angiogenic therapies for the treatment of angiosarcoma: a clinical update","volume":"10","author":"Young","year":"2017","journal-title":"Memo"},{"key":"10.1016\/j.esmoop.2025.106018_bib29","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/532478","article-title":"Phase II trial of gemcitabine and docetaxel with bevacizumab in soft tissue sarcoma","volume":"2015","author":"Dickson","year":"2015","journal-title":"Sarcoma"},{"issue":"10","key":"10.1016\/j.esmoop.2025.106018_bib30","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1158\/2326-6066.CIR-19-0149","article-title":"Microsatellite-stable tumors with high mutational burden benefit from immunotherapy","volume":"7","author":"Goodman","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.esmoop.2025.106018_bib31","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1253657","article-title":"Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma","volume":"6","author":"Honda","year":"2017","journal-title":"Oncoimmunology"},{"issue":"16","key":"10.1016\/j.esmoop.2025.106018_bib32","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.7150\/jca.19060","article-title":"Programmed death ligand 1 (PD-L1) expression in primary angiosarcoma","volume":"8","author":"Botti","year":"2017","journal-title":"J Cancer"},{"key":"10.1016\/j.esmoop.2025.106018_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115537","article-title":"Phase II trial dedicated to non-selected, pretreated cutaneous angiosarcoma: efficacy of nivolumab (AngioCheck Study)","volume":"224","author":"Fujisawa","year":"2025","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2025.106018_bib34","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/jamaoncol.2019.6152","article-title":"Objective response rate among patients with locally advanced or metastatic sarcoma treated With talimogene laherparepvec in combination with pembrolizumab: a phase 2 clinical trial","volume":"6","author":"Kelly","year":"2020","journal-title":"JAMA Oncol"},{"issue":"15","key":"10.1016\/j.esmoop.2025.106018_bib35","article-title":"Alliance A091902: a multicenter randomized phase II trial of paclitaxel (P) with or without nivolumab (N) in patients (pts) with advanced angiosarcoma (AS)","volume":"42","author":"Grilley-Olson","year":"2024","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.esmoop.2025.106018_bib36","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1158\/1078-0432.CCR-25-0311","article-title":"Cemiplimab in locally advanced or metastatic secondary angiosarcomas (CEMangio): a phase II clinical trial and biomarker analyses","volume":"31","author":"van Ravensteijn","year":"2025","journal-title":"Clin Cancer Res"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925018885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925018885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T16:29:40Z","timestamp":1771864180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925018885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2059702925018885"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.106018","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II trial, multicenter, first-line paclitaxel-avelumab treatment of inoperable angiosarcoma (KCSG UN 18-15)","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.106018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106018"}}